Fathiya El-Raey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fathiya El-Raey has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Alboraie
Al-Azhar University
5 shared publications - Naglaa Youssef
Medical-Surgical Nursing Department, Faculty of Nursing, Cairo University, Giza, Egypt
4 shared publications - Samy Zaky
Al-Azhar University, Cairo, Egypt
3 shared publications Aimable Nzabonimana
Center for Language Enhancement, College of Arts and Social Sciences, University of Rwanda, Huye, Rwanda
2 shared publications- Amin Abdel Baki
Department Hepatology, Gastroenterology and Infectious diseases National Hepatology and Tropical Medicine Research Institute NHTMRI, Cairo, Egypt
2 shared publications - Angela Chiu Yin Poon
Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao, China
2 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1)
Safety and efficacy of mirikizumab as induction and maintenance for inflammatory bowel disease in adult patients: a systematic review and meta-analysis
Background: Mirikizumab, a monoclonal antibody targeting interleukin-23 (IL-23), was studied for adult patients with moderate-to-severe inflammatory bowel disease (IBD). However, conflicting evidence exists on its safety, efficacy and optimal dosing strategy. Aim: To evaluate the safety and efficacy of mirikizumab in treating IBD and understand a dose–response relationship based on clinical, endoscopic, and histological outcomes. Methodology: A systematic search of six electronic databases, i.e. PubMed, ClinicalTrials.gov, Cochrane CENTRAL, ScienceDirect, ProQuest, and EBSCO, was conducted (PROSPERO: CRD42024570804). Relevant data were extracted from selected studies. Primary endpoints included safety, efficacy, adverse events (AEs), serious adverse events (SAEs), and mortality. Dose–response relationship was assessed as a secondary endpoint. Results: Six trials were eligible from 415 screened records, pooling 3,990 participants (3,073 of whom received mirikizumab). Mirikizumab significantly improved clinical remission (relative risk [RR] [95% CI] = 1.87 [1.57–2.22]) and histological outcomes (RR [95% CI] = 1.63 [1.35–1.97]) with minimal heterogeneity across subgroups, i.e. intravenous (IV) and subcutaneous (SC) routes. The drug significantly improved endoscopic remission (RR [95% CI] = 1.66 [1.28–2.16]), particularly with IV route (RR = 2.09). The risk for AEs was similar between groups, with low heterogeneity (I 2 = 2.0%). Conclusion: Mirikizumab improves clinical, histological, and endoscopic outcomes in IBD with a favorable safety profile. There was no significant difference with different injection routes and with incrementing dose beyond 200 mg.
- 21 May 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1)
Open AccessSafety and efficacy of mirikizumab as induction and maintenance for inflammatory bowel disease in adult patients: a systematic review and meta-analysis
Background: Mirikizumab, a monoclonal antibody targeting interleukin-23 (IL-23), was studied for adult patients with moderate-to-severe inflammatory bowel disease (IBD). However, conflicting evidence exists on its safety, efficacy and optimal dosing strategy. Aim: To evaluate the safety and efficacy of mirikizumab in treating IBD and understand a dose–response relationship based on clinical, endoscopic, and histological outcomes. Methodology: A systematic search of six electronic databases, i.e. PubMed, ClinicalTrials.gov, Cochrane CENTRAL, ScienceDirect, ProQuest, and EBSCO, was conducted (PROSPERO: CRD42024570804). Relevant data were extracted from selected studies. Primary endpoints included safety, efficacy, adverse events (AEs), serious adverse events (SAEs), and mortality. Dose–response relationship was assessed as a secondary endpoint. Results: Six trials were eligible from 415 screened records, pooling 3,990 participants (3,073 of whom received mirikizumab). Mirikizumab significantly improved clinical remission (relative risk [RR] [95% CI] = 1.87 [1.57–2.22]) and histological outcomes (RR [95% CI] = 1.63 [1.35–1.97]) with minimal heterogeneity across subgroups, i.e. intravenous (IV) and subcutaneous (SC) routes. The drug significantly improved endoscopic remission (RR [95% CI] = 1.66 [1.28–2.16]), particularly with IV route (RR = 2.09). The risk for AEs was similar between groups, with low heterogeneity (I 2 = 2.0%). Conclusion: Mirikizumab improves clinical, histological, and endoscopic outcomes in IBD with a favorable safety profile. There was no significant difference with different injection routes and with incrementing dose beyond 200 mg.
- Open Access
- 14 February 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04091
Individuals’ positive gains from the COVID-19 pandemic: a qualitative study across 30 countries
The COVID-19 pandemic, an unprecedented global crisis, has indelibly reshaped all facets of life globally – health, economy, environment, and societal fabric [1–3]. Major societal events are often transformative. The predominant focus on the pandemic’s negative impacts, necessitates a more balanced perspective to prevent a skewed understanding of its overall impacts. Additionally, unveiling the hidden […]
- 14 February 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04091
Open AccessIndividuals’ positive gains from the COVID-19 pandemic: a qualitative study across 30 countries
The COVID-19 pandemic, an unprecedented global crisis, has indelibly reshaped all facets of life globally – health, economy, environment, and societal fabric [1–3]. Major societal events are often transformative. The predominant focus on the pandemic’s negative impacts, necessitates a more balanced perspective to prevent a skewed understanding of its overall impacts. Additionally, unveiling the hidden […]
- Open Access
- 10 January 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04011
Country-specific key lifestyle factors and health outcomes for resource allocation in the general population: a network analysis across 29 countries
Lifestyle factors – including dietary risks, alcohol and tobacco consumption, sedentary behaviours, and physical inactivity – significantly influence health outcomes both immediately and over the long term. Short-term impacts manifest in changes to physical and psychological quality of life [1], sleep [2], and social well-being [3]. Conversely, persistent unhealthy lifestyle behaviours substantially elevate the risk […]
- 10 January 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04011
Open AccessCountry-specific key lifestyle factors and health outcomes for resource allocation in the general population: a network analysis across 29 countries
Lifestyle factors – including dietary risks, alcohol and tobacco consumption, sedentary behaviours, and physical inactivity – significantly influence health outcomes both immediately and over the long term. Short-term impacts manifest in changes to physical and psychological quality of life [1], sleep [2], and social well-being [3]. Conversely, persistent unhealthy lifestyle behaviours substantially elevate the risk […]
- 23 April 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (2) , 314-320
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C
- 23 April 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (2) , 314-320
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C
- Open Access
- 12 March 2022
- Published by Wiley in International Journal of Telemedicine and Applications
- Vol. 2022, 1-8
Healthcare Providers’ Perspective about the Use of Telemedicine in Egypt: A National Survey
Incorporation of telemedicine in general clinical practice is becoming a compelling need nowadays in the context of COVID-19 pandemic and its consequent burdens on the healthcare systems. Though telemedicine appears to be appealing and carries a lot of advantages, yet it is still faced by many challenges and barriers especially in developing countries. Our aim was to explore the impression of healthcare providers about telemedicine and its applicability in clinical practice in Egypt. A cross-sectional study was conducted among healthcare providers from different Egyptian governorates through a web-based survey. The survey gathered information about demographic, socioeconomic features of the enrolled healthcare participants; their knowledge, previous experience, impression about telemedicine, advantages of telemedicine over traditional medical services, barriers that may face telemedicine, and additional services that can be provided by telemedicine were also explored. Our study enrolled 642 healthcare providers from all over Egypt, 43.77% were females, of which 55.5% were physicians, 27.3% were nurses, 6.1% were technicians, 7.6% were administrative clerks, and 3.6% were medical directors. Sixty-four percent of participants reported that they have never used telemedicine. Smartphones were the most commonly used mean in the group who used telemedicine (65%), and smartphone applications were the favorable telemedicine service for about 50% of participants. Participants assumed that the use of telemedicine might not have a negative effect on the doctor-patient relationship but raised some concerns regarding the privacy and security of patients’ data. Despite the fact that telemedicine appears to be appealing and widely accepted by healthcare providers, yet still, its implementation is confronted by some obstacles. Precise organizational guidelines need to be developed to clearly figure out the exact role of each healthcare provider to minimize their doubtfulness about telemedicine and to facilitate its adoption.
- 12 March 2022
- Published by Wiley in International Journal of Telemedicine and Applications
- Vol. 2022, 1-8
Open AccessHealthcare Providers’ Perspective about the Use of Telemedicine in Egypt: A National Survey
Incorporation of telemedicine in general clinical practice is becoming a compelling need nowadays in the context of COVID-19 pandemic and its consequent burdens on the healthcare systems. Though telemedicine appears to be appealing and carries a lot of advantages, yet it is still faced by many challenges and barriers especially in developing countries. Our aim was to explore the impression of healthcare providers about telemedicine and its applicability in clinical practice in Egypt. A cross-sectional study was conducted among healthcare providers from different Egyptian governorates through a web-based survey. The survey gathered information about demographic, socioeconomic features of the enrolled healthcare participants; their knowledge, previous experience, impression about telemedicine, advantages of telemedicine over traditional medical services, barriers that may face telemedicine, and additional services that can be provided by telemedicine were also explored. Our study enrolled 642 healthcare providers from all over Egypt, 43.77% were females, of which 55.5% were physicians, 27.3% were nurses, 6.1% were technicians, 7.6% were administrative clerks, and 3.6% were medical directors. Sixty-four percent of participants reported that they have never used telemedicine. Smartphones were the most commonly used mean in the group who used telemedicine (65%), and smartphone applications were the favorable telemedicine service for about 50% of participants. Participants assumed that the use of telemedicine might not have a negative effect on the doctor-patient relationship but raised some concerns regarding the privacy and security of patients’ data. Despite the fact that telemedicine appears to be appealing and widely accepted by healthcare providers, yet still, its implementation is confronted by some obstacles. Precise organizational guidelines need to be developed to clearly figure out the exact role of each healthcare provider to minimize their doubtfulness about telemedicine and to facilitate its adoption.
- 28 December 2021
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 17 (12) , 1473-1480
Utility of Lung Ultrasound in Decision-making to Prioritize Hospital Admission for COVID-19 Patients: A Developing Country Perspective
Background & Aims: In healthcare settings with limited resources, it is crucial to make a plan to prioritize hospital admission for patients affected by COVID-19. So, we tried to develop a novel approach for triaging COVID-19 patients and deciding the priority for hospital admission using Lung Ultrasound. In this study, we aimed to evaluate the efficacy of lung ultrasound in triaging suspected COVID-19 patients and assessment of the severity of COVID-19 pneumonia and its comparison with CT chest as the gold standard. Method: This was a multicenter cross-sectional study enrolled on 243 COVID-19 confirmed patients presented to the emergency department in three major University hospitals in Egypt. Lung ultrasound was done by an experienced emergency physician or chest physician according to the local protocol of each hospital. Demographic, clinical, and laboratory data were collected from each patient. Each patient was subjected to CT chest and lung ultrasound. Results: A total of 243 confirmed COVID-19 patients were enrolled in this study, with a mean age of 46.7+10.4 years. Ground glass opacity (GGO), subpleural consolidation, trans-lobar consolidation, and crazy paving were reported in chest CT scans of 54.3%, 15.2%, 11.1%, and 8.6% of patients, respectively. B-line artifacts were found in 81.1% of COVID-19 patients, which was of confluent pattern in 18.9% of patients. The lung ultrasound findings of 197 patients (81.1%) were completely coincident with those of CT with a Kappa agreement value of 0.77, and this offered a diagnostic sensitivity of 74 %, a diagnostic specificity of 97.9 %, positive predictive value (PPV) of 90.2% and negative predictive value (NPV) of 93.6 % for lung ultrasound in triaging COVID-19 patients. Adding O2 saturation to the findings of lung imaging, the accuracy of evaluation of lung ultrasound to differentiate between severe and non-severe lung diseases showed that ultrasound had 100% sensitivity and specificity. Conclusion: Lung Ultrasound with Oxygen saturation is a very efficient tool for decision-making to prioritize hospital admission for patients affected by COVID-19 in healthcare settings with limited resources.
- 28 December 2021
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 17 (12) , 1473-1480
Utility of Lung Ultrasound in Decision-making to Prioritize Hospital Admission for COVID-19 Patients: A Developing Country Perspective
Background & Aims: In healthcare settings with limited resources, it is crucial to make a plan to prioritize hospital admission for patients affected by COVID-19. So, we tried to develop a novel approach for triaging COVID-19 patients and deciding the priority for hospital admission using Lung Ultrasound. In this study, we aimed to evaluate the efficacy of lung ultrasound in triaging suspected COVID-19 patients and assessment of the severity of COVID-19 pneumonia and its comparison with CT chest as the gold standard. Method: This was a multicenter cross-sectional study enrolled on 243 COVID-19 confirmed patients presented to the emergency department in three major University hospitals in Egypt. Lung ultrasound was done by an experienced emergency physician or chest physician according to the local protocol of each hospital. Demographic, clinical, and laboratory data were collected from each patient. Each patient was subjected to CT chest and lung ultrasound. Results: A total of 243 confirmed COVID-19 patients were enrolled in this study, with a mean age of 46.7+10.4 years. Ground glass opacity (GGO), subpleural consolidation, trans-lobar consolidation, and crazy paving were reported in chest CT scans of 54.3%, 15.2%, 11.1%, and 8.6% of patients, respectively. B-line artifacts were found in 81.1% of COVID-19 patients, which was of confluent pattern in 18.9% of patients. The lung ultrasound findings of 197 patients (81.1%) were completely coincident with those of CT with a Kappa agreement value of 0.77, and this offered a diagnostic sensitivity of 74 %, a diagnostic specificity of 97.9 %, positive predictive value (PPV) of 90.2% and negative predictive value (NPV) of 93.6 % for lung ultrasound in triaging COVID-19 patients. Adding O2 saturation to the findings of lung imaging, the accuracy of evaluation of lung ultrasound to differentiate between severe and non-severe lung diseases showed that ultrasound had 100% sensitivity and specificity. Conclusion: Lung Ultrasound with Oxygen saturation is a very efficient tool for decision-making to prioritize hospital admission for patients affected by COVID-19 in healthcare settings with limited resources.
- Open Access
- 9 June 2021
- Published by Wiley in International Journal of Telemedicine and Applications
- Vol. 2021, 1-8
Knowledge, Applicability, and Barriers of Telemedicine in Egypt: A National Survey
Objectives. The study is aimed at evaluating knowledge, attitude, and barriers to telemedicine among the general population in Egypt. Methods. A questionnaire-based cross-sectional design was carried out among the general Egyptian population. A convenience sampling method was used to approach the eligible participants from University Teaching Hospitals of eight governorates from May to July 2020. Results. A total of 686 participants filled the questionnaire (49.4% were males, mean age years old). Half of the participants stated that they previously used a telemedicine tool, mainly to follow up laboratory results (67.3%). Video or phone calls (39.3%) and mobile applications (23.7%) were the most commonly recognized telemedicine tools by the participants. The included participants exhibited a high level of knowledge and attitude towards telemedicine. On the other hand, 21.9% stated that telemedicine services could jeopardize patient privacy. 32.8% reported that telemedicine service could lead to disclosing medical information to people who are not authorized to do so. Almost half of the participants agreed to strongly agreed that telemedicine service could increase medical errors. 60.80% of the participants said that they are more likely to prefer telemedicine than traditional ways. However, 13.70% stated that telemedicine is more likely to be challenging to use. Conclusion. The Egyptian population has high knowledge about the applications of telemedicine. In addition, the vast majority of Egyptians appear to perceive the benefits of telemedicine positively and are willing to use it. However, some barriers that have been found must be taken into consideration to adopt telemedicine successfully, especially for people who are old, are low educated, and live in remote areas. Future studies should address the utility of telemedicine in improving the quality of healthcare and patient’s health outcome and quality of life.
- 9 June 2021
- Published by Wiley in International Journal of Telemedicine and Applications
- Vol. 2021, 1-8
Open AccessKnowledge, Applicability, and Barriers of Telemedicine in Egypt: A National Survey
Objectives. The study is aimed at evaluating knowledge, attitude, and barriers to telemedicine among the general population in Egypt. Methods. A questionnaire-based cross-sectional design was carried out among the general Egyptian population. A convenience sampling method was used to approach the eligible participants from University Teaching Hospitals of eight governorates from May to July 2020. Results. A total of 686 participants filled the questionnaire (49.4% were males, mean age years old). Half of the participants stated that they previously used a telemedicine tool, mainly to follow up laboratory results (67.3%). Video or phone calls (39.3%) and mobile applications (23.7%) were the most commonly recognized telemedicine tools by the participants. The included participants exhibited a high level of knowledge and attitude towards telemedicine. On the other hand, 21.9% stated that telemedicine services could jeopardize patient privacy. 32.8% reported that telemedicine service could lead to disclosing medical information to people who are not authorized to do so. Almost half of the participants agreed to strongly agreed that telemedicine service could increase medical errors. 60.80% of the participants said that they are more likely to prefer telemedicine than traditional ways. However, 13.70% stated that telemedicine is more likely to be challenging to use. Conclusion. The Egyptian population has high knowledge about the applications of telemedicine. In addition, the vast majority of Egyptians appear to perceive the benefits of telemedicine positively and are willing to use it. However, some barriers that have been found must be taken into consideration to adopt telemedicine successfully, especially for people who are old, are low educated, and live in remote areas. Future studies should address the utility of telemedicine in improving the quality of healthcare and patient’s health outcome and quality of life.
- 1 February 2021
- Published by Georg Thieme Verlag KG in Journal of Pediatric Infectious Diseases
- Vol. 16 (02) , 057-061
COVID-19 in Egyptian Children: A Multicenter Study
Objective The novel coronavirus disease 2019 (COVID-19) has made its worldwide spread since its outbreak in December 2019. Limited information is available about the epidemiology and clinical characteristics of COVID-19, especially in Africa and Egypt. Methods We aimed to study the clinical and epidemiological characteristics of COVID-19 in Egyptian children. This is an observational retrospective cohort study performed at two specialized COVID-19 isolation hospitals in Egypt. All admitted COVID-19 pediatric patients between March 20, 2020, and May 1, 2020, were included in the study. Discussion This study included 40 COVID-19 confirmed cases (mean age, 9.4 years), 67.5% were male, 85% were asymptomatic, and 15% had mild symptoms. There were no confirmed severe or critically ill cases among the patients. Conclusion COVID-19 runs in a benign course in Egyptian children with no mortality and no significant morbidity.
- 1 February 2021
- Published by Georg Thieme Verlag KG in Journal of Pediatric Infectious Diseases
- Vol. 16 (02) , 057-061
COVID-19 in Egyptian Children: A Multicenter Study
Objective The novel coronavirus disease 2019 (COVID-19) has made its worldwide spread since its outbreak in December 2019. Limited information is available about the epidemiology and clinical characteristics of COVID-19, especially in Africa and Egypt. Methods We aimed to study the clinical and epidemiological characteristics of COVID-19 in Egyptian children. This is an observational retrospective cohort study performed at two specialized COVID-19 isolation hospitals in Egypt. All admitted COVID-19 pediatric patients between March 20, 2020, and May 1, 2020, were included in the study. Discussion This study included 40 COVID-19 confirmed cases (mean age, 9.4 years), 67.5% were male, 85% were asymptomatic, and 15% had mild symptoms. There were no confirmed severe or critically ill cases among the patients. Conclusion COVID-19 runs in a benign course in Egyptian children with no mortality and no significant morbidity.
- Open Access
- 4 February 2020
- Published by Egyptian Knowledge Bank in International Journal of Medical Arts
Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease (ESRD) on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir (OBV) 25 mg /paritaprevir (PTV) 150 mg /ritonavir (RTV) 100 mg plus generic ribavirin (RBV) 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40(87.5%)] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients (12.2%). As these patients were not responding to anemia correction measures (blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose). Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis.
- 4 February 2020
- Published by Egyptian Knowledge Bank in International Journal of Medical Arts
Open AccessEfficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease (ESRD) on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir (OBV) 25 mg /paritaprevir (PTV) 150 mg /ritonavir (RTV) 100 mg plus generic ribavirin (RBV) 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40(87.5%)] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients (12.2%). As these patients were not responding to anemia correction measures (blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose). Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis.